Substantial Change number 2: 1. The non-inclusion criterion "Previous treatment with Bevacizumab", appearing in the section "Prohibited concomitant treatment" has been added in the synopsis and in the non-inclusion criteria section. 2. To coincide with the maximum time frame for SAEs reporting, the time frame for the end-of-study review was changed to 30 days instead of 3 weeks. 3. In the "serious adverse events" chapter: - definition of SAEs not considered serious (e.g. hospitalization <24h); - addition of a chapter on notification to the competent authorities; - addition of a chapter on notification to BAYER SCHERING Pharma. 4. It was specified that the statistical analysis will be performed according to the stratification factors defined in the protocol. 5. To comply with the product's marketing authorization and because of its half-life, the frequency of drug intake in case of dose reduction was corrected to : 2 x 200mg 1 time/day. 6. The study schedule has been corrected. Indeed, the histological confirmation at day 15 is a typographical error.

Substantial Change number 4: The major changes include: 1. Interim analysis on the primary endpoint, which is progression-free survival at 9 months. In summary, 44 and 24 patients should be included in strata A and B respectively with p0 = 0.13 and p1= 0.32 (expected progression-free survival at 9 months), alpha = 0.10, and a power of 95% and 81% in strata A and B strata, respectively. This design allows for an interim analysis in each stratum after inclusion of 24 and 12 patients, with a stopping decision if more than 20 progressions out of 24 patients before 9 months in stratum A and more than 10 progressions out of 12 patients before 9 months in stratum B. 2. Creation of Stratum C: Epithelioid hemangioendotheliomas, hemangiopericytomas and malignant solitary fibrous tumors. There are three arguments in favor of creating this stratum: - The favorable benefit/risk ratio of Sorafenib for angiosarcoma observed in the 1st IDMC - The absence of a therapeutic standard for other vascular sarcomas (epithelioid hemangioendotheliomas and hemangiopericytomas) - The biological rationale suggesting efficacy in these situations.

Rationale for Substantial Change number 5: 1. The creation of a D stratum: chordomas The rationale behind the addition of this new stratum is based on: - The lack of a therapeutic standard, - Prolonged stabilization with the use of targeted therapies such as tyrosine kinase inhibitors (while chemotherapies remain ineffective) ineffective), - Characterization by expression of a functional target of Sorafenib, suggesting its efficacy in this indication This stratum will include 25 patients with metastatic and progressive chordoma. The clinical studies on which the rationale is based were conducted in limited on limited cohorts, which does not allow for statistical hypothesis. The benefit/risk ratio within this stratum will be reviewed on a semi-annual basis by semi-annually by the IDMC set up for this study. Therefore, changes are being made to the protocol regarding inclusion criteria, study duration and total number of patients. 2. Update of the Nexavar summary of product characteristics This document was revised on January 5, 2011, and mentions new data : - warnings and precautions for use, - fatal or life-threatening adverse events (see table below). This new version cancels and replaces the current reference document in this study. The information and consent note for patients includes these elements. 3. Change in telephone and monitor contact information 4. Updated Declaration of Helsinki